-
Ana Méndez-Echevarr'ia,
Miguel González-Muñoz,
Maria Jose Mellado,
Fernando Baquero-Artigao,
Daniel Blázquez,
Mar'ia Pen'in, Maria Luisa Navarro,
Jesús Saavedra-Lozano,
Maria Teresa Hernandez-Sampelayo,
Isabel González-Tomé,
Cristina Calvo,
Marta Ruiz,
Jose Tomás Ramos,
Sara Guillén,
Ramón Velazquez,
Beatriz Pérez,
Jorge Mart'inez,
Elia Pérez
Archives of Disease in Childhood 06/2012; 97(6):514-6. · 2.88 Impact Factor
-
Ana Méndez-Echevarría,
Miguel González-Muñoz,
Maria Jose Mellado,
Fernando Baquero-Artigao,
Daniel Blázquez,
María Penín, Maria Luisa Navarro,
Jesús Saavedra-Lozano,
Maria Teresa Hernandez-Sampelayo,
Isabel González-Tomé,
Cristina Calvo,
Marta Ruiz,
Jose Tomás Ramos,
Sara Guillén,
Ramón Velazquez,
Beatriz Pérez,
Jorge Martínez,
Elia Pérez
[show abstract]
[hide abstract]
ABSTRACT: To compare the QuantiFERON-TB GOLD In Tube test (QTF) and the tuberculin skin test (TST) in children.
A prospective study was carried out in nine hospitals in Madrid, Spain. TST and QTF were performed in immigrants, tuberculosis (TB) contacts and patients with TB disease (TBD).
459 children were included. Disagreement between the tests was more frequently observed among latent tuberculosis infection (LTBI) cases (54%; 38/70) than in non-infected or TBD cases (0.8%; 3/369) (p<0.01). There were more BCG-vaccinated children among LTBI cases with negative QTF (76%) than among LTBI cases with positive QTF (40%) (p<0.001). Agreement between tests in BCG-vaccinated children was lower than in non-vaccinated cases (p<0.05). Tests in TB exposed patients showed better agreement than in non-exposed children (p<0.05).
Agreement of both tests was excellent in TBD cases, non-vaccinated children and non-infected patients. A significant number of QTF negative results were observed among LTBI cases, especially in BCG-vaccinated children. Agreement was better in exposed children.
Archives of Disease in Childhood 05/2011; 97(6):514-6. · 2.88 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The use of atazanavir (ATV) in adolescents infected with human immunodeficiency virus was analyzed in this study. ATV morning plasma concentrations were determined during regular visits to the outpatient department. Results showed that bilirubin levels were higher among patients with higher ATV plasma concentrations (p = .018). Monitoring plasma levels of ATV could avoid toxicity in these patients.
Journal of Adolescent Health 01/2011; 48(1):100-2. · 3.33 Impact Factor
-
Juan C Tejedor,
Manuel Moro,
Jesus Ruiz-Contreras,
Javier Castro,
Jose A Gómez-Campderá, Maria Luisa Navarro,
Jose Manuel Merino,
Ana Martín-Ancel,
Joan Roca,
Manuel García-del-Río,
Antonio Jurado,
Francisco Javier Díez-Delgado,
Felix Omeñaca,
Jose García-Sicilia,
Reyes Boceta,
Pilar García-Corbeira,
Jeanne-Marie Jacquet,
Alix Collard,
Lode Schuerman
[show abstract]
[hide abstract]
ABSTRACT: This study evaluated the concurrent use of meningococcal C tetanus conjugate (MenC-TT) vaccine (NeisVac-C) with DTaP-based combinations, according to 2 vaccination schedules, one of which included hepatitis B vaccination at birth (Trial DTaP-HBV-IPV/Hib-097).
Healthy infants were randomized to receive either DTaP-HBV-IPV/Hib (Infanrix hexa) at 2, 4, and 6 months (N = 115) or HBV at birth followed by DTaP-HBV-IPV/Hib at 2 and 6 months and DTaP-IPV/Hib (Infanrix-IPV Hib) at 4 months (N = 115). In both groups 2 doses of MenC-TT conjugate were coadministered at 2 and 4 months, and compared with 3 doses of MenC-CRM197 conjugate (Meningitec) coadministered at 2, 4, and 6 months with DTaP-HBV-IPV/Hib (N = 120). Antibody concentrations were measured at 2, 6 and 7 months. Solicited local and general symptoms, unsolicited symptoms, and serious adverse events (SAEs) were recorded.
All MenC-TT recipients had seroprotective concentrations of anti-PRP antibodies (> or = 0.15 microg/mL) 1 month after the third vaccine dose and all had SBA-MenC titers > or = 1:8 after the second dose of MenC-TT. These responses were noninferior to those seen after 3 doses of DTaP-HBV-IPV/Hib and MenC-CRM. Anti-PRP antibody GMCs were significantly higher in MenC-TT than MenC-CRM vaccinees (7.9, 7.3, 3.8 microg/mL, respectively). Immune responses to all other coadministered antigens were unimpaired, with seroprotection/seropositivity rates > or = 98.1% in MenC-TT vaccinees. All schedules studied were well tolerated, with no differences in reactogenicity between the study groups.
Coadministration of DTaP-HBV-IPV/Hib or DTaP-IPV/Hib with 2 doses of MenC-TT conjugate vaccine is safe, well tolerated, and immunogenic, with no impairment of the response to the coadministered antigens.
The Pediatric Infectious Disease Journal 08/2006; 25(8):713-20. · 3.58 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To study the control of viral replication in human immunodeficiency virus (HIV)-infected children on different salvage therapies.
A retrospective observational study in 120 HIV-infected children was conducted. The children were divided into 3 groups according to their salvage therapies: (1) children receiving first line highly active antiretroviral therapy (HAART); (2) protease inhibitor-experienced children receiving second line HAART; (3) protease inhibitor-experienced children receiving HAART including lopinavir-ritonavir (LPV/r). The outcome variables examined were time to achieve viral load (VL) < or =400 copies/mL, success in achieving VL < or =400 copies/mL and time to virologic failure (VL >400 copies/mL).
VL (HIV-RNA copies/mL) was quantified with reverse transcription-polymerase chain reaction molecular assay. For each protocol, survival analyses were conducted to determine the probability of achieving VL < or =400 copies/mL and rebound of VL.
VL < or =400 copies/mL was achieved by 52.4% of children receiving first line HAART, 48.3% receiving second line HAART and 71.5% receiving HAART including LPV/r. Children receiving HAART including LPV/r reached VL < or =400 copies/mL in a shorter time than children receiving second line HAART (P = 0.017), but quite similar to children receiving first line HAART. In terms of adjusted relative risk, children receiving HAART including LPV/r were 3.36 [95% confidence interval (95% CI), 1.59, 7.07] more likely to achieve VL < or =400 copies/mL than children receiving a different second line HAART. VL rebound occurred in 68.2% children receiving first line HAART, 73.4% receiving second line HAART and 32.4% receiving HAART including LPV/r. Children receiving HAART that includes LPV/r has less incidence of VL rebound (P=0.013) and 3.29 (95% CI 1.04, 10.3) times less risk to achieve a VL rebound than children receiving a different second line HAART.
HAART that includes LPV/r is able to control HIV replication more efficiently than other classic salvage antiretroviral therapies.
The Pediatric Infectious Disease Journal 10/2004; 23(10):923-30. · 3.58 Impact Factor
